Remove 2014 Remove Healthcare Remove Safety
article thumbnail

Norstella, Citeline merge to create $5bn pharma tech firm

pharmaphorum

It has now joined Norstella’s four group companies – pharma intelligence unit Evaluate, market access specialist MMIT, healthcare data analytics software provider Panalgo and market access consultancy The Dedham Group – which were combined under the Norstella banner in May.

Pharma 101
article thumbnail

Tributes as former NICE, MHRA chair Sir Mike Rawlins dies

pharmaphorum

The UK healthcare sector is mourning one of the most eminent of its figures in the last few decades – Professor Sir Mike Rawlins – who has passed away at the age of 81. ” The post Tributes as former NICE, MHRA chair Sir Mike Rawlins dies appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

Tentative approval means Lumryz has satisfied all the FDA requirements for efficacy, safety, and quality standards, but it can’t be fully approved until a patent or other exclusivity expires. Furthermore, Molina stated Jazz “suppressed generic competition and raised the price of Xyrem 841% between 2007 and 2014.” About the author.

article thumbnail

Securing every dose with an edible security technology for safe medicines

European Pharmaceutical Review

FAKE MEDICINES are not a new problem, and pose a tremendous threat to patient safety and public health in society regardless of a country’s economic status. We hope that this article serves draws attention from the community and makes funding agencies aware of this imperative healthcare sustainability problem. About the author.

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

The FDA’s role in the regulation of botanical drug products includes an assessment of their safety and efficiency 5 but insufficient evidence for efficacy is one of the most common reasons why new drug candidates fail to reach this step. 6 Thus, it is critical to ensure the consistency of therapeutic effect across batches (see box).

Marketing 103
article thumbnail

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part i)

pharmaphorum

The present moment within and without healthcare, biotech, and pharma is a difficult and pivotal time in history, a time in which such issues need must be addressed. The keynote address of the event entire came from Stella Kyriakides, commissioner for health and food safety at the European Commission. Her opener?

article thumbnail

Centerline Biomedical Raises $33 Million in Series B Financing

Legacy MEDSearch

Centerline), a private medical technology company, announced the closing of a $33 million Series B equity financing led by Cleveland Clinic with participation by GE Healthcare, RIK Enterprises, JobsOhio, Jumpstart Ventures and G2 Group Ventures. Founded in 2014, Centerline Biomedical is headquartered in Cleveland, Ohio.